Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Trial Profile

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms REASSURE
  • Sponsors Bayer
  • Most Recent Events

    • 12 Sep 2017 First interim analysis results (n=583) presented at the 42nd European Society for Medical Oncology Congress
    • 01 Sep 2017 According to a Bayer media release, first interim results will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
    • 22 Aug 2017 Planned number of patients changed from 1334 to 1440.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top